Status:
COMPLETED
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with Type 2 diabetes on metformin (Parts ...
Eligibility Criteria
Inclusion
- Key Inclusion Criteria for participants enrolling with T2DM:
- Type 2 Diabetes treated with a stable dose of metformin at least 500 mg per day for at least 2 months prior to screening visit and use of no other medications for glycemic control.
- HbA1c value between 7.0% and 10.5%, inclusive.
- Key Exclusion Criterion for participants enrolling with T2DM:
- Type 1 Diabetes or secondary forms of diabetes.
- Key Inclusion Criterion for participants enrolling with obesity:
- Obese (as indicated by screening BMI) non-diabetic adults.
- Key Exclusion Criterion for participants enrolling with obesity:
- -Type 1 or Type 2 Diabetes or secondary forms of diabetes.
Exclusion
Key Trial Info
Start Date :
March 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 14 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04305587
Start Date
March 16 2020
End Date
July 14 2021
Last Update
February 5 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801
2
Qps-Mra, Llc
South Miami, Florida, United States, 33143